SUPN · Supernus Pharmaceuticals, Inc.
$46.20
+1.60% last session
End-of-day data · updated 2026-07-28
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
10.8
Dividend yield
—
Beta
0.54
Avg volume
1M
Employees
1K
2D change
—
5D change
-0.45%
10D change
-2.21%
30D change
0.30%
60D change
1.73%
MTD change
-0.91%
YTD change
-5.47%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SUPN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-09
Latest call per bank · past 12 months
Bank of America
Buy$65.00
+40.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-09 | Cantor Fitzgerald | Maintains | Overweight | $63.00 → $67.00 |
| 2025-12-19 | Stifel | Maintains | Hold | $50.00 → $55.00 |
| 2025-10-29 | Bank of America | Initiates | Buy | $0.00 → $65.00 |
| 2025-10-23 | TD Cowen | Maintains | Buy | $45.00 → $60.00 |
| 2025-10-09 | Piper Sandler | Upgrade | Neutral → Overweight | $40.00 → $65.00 |
| 2025-09-30 | Cantor Fitzgerald | Maintains | Overweight | $46.00 → $63.00 |
| 2025-08-29 | Piper Sandler | Maintains | Neutral | $36.00 → $40.00 |
| 2025-08-06 | Cantor Fitzgerald | Maintains | Overweight | $42.00 → $46.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 53 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.3% above the 50-day MA ($46.65).
- Price vs 200-day MA: Trading 2.8% below the 200-day MA ($49.08).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.08) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($33.41) and high ($57.00).
SUPN Price Chart
Loading chart for SUPN…
Fundamentals
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.